Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
While anticoagulation therapy is generally effective for stroke prevention in patients with atrial fibrillation (AF), its benefit in patients with kidney failure undergoing hemodialysis has not been clearly established, and concerns regarding increased bleeding complications persist. Previous studies may not have fully accounted for immortal time bias and competing risks. This study aimed to evaluate the association between anticoagulation therapy and clinical outcomes in hemodialysis patients with AF using a target trial emulation framework with the clone-censor-weight method.
Using the DeSC database, an administrative claims database in Japan, we identified patients undergoing maintenance hemodialysis who were newly diagnosed with AF between April 2014 and July 2024. We emulated a target trial by creating cloned cohorts for two treatment strategies: initiation versus non-initiation of oral anticoagulation within 90 days of diagnosis. Patients were censored and inversely weighted if their treatment deviated from the assigned strategy. Follow-up started on the date of the first AF diagnosis and ended at the occurrence of an event, death, one year after baseline, or disenrollment from the database, whichever occurred first. The outcomes of interest were ischemic stroke and intracerebral hemorrhage requiring hospitalization or treatment and all-cause death. We calculated the difference in the one-year cumulative incidence of outcomes between the two groups, accounting for the competing risk of death and adjusting for 49 clinically relevant variables. The 95% confidence interval was estimated using 200 bootstrap resamples.
The study included 4,634 eligible patients (mean age, 77 years; 67% male), of whom 644 initiated oral anticoagulation therapy within 90 days of diagnosis. At one year, the risk difference between the initiation and non-initiation groups was 1.0 percentage points (pp) for intracerebral hemorrhage (3.0% vs. 1.9%; 95% confidence interval [CI], -0.2 to 2.5), 0.1 pp for ischemic stroke (5.2% vs. 5.0%; 95% CI, -1.5 to 1.8), -2.5 pp (33.0% vs. 35.6%; 95% CI, -6.1 to 1.1).
In patients with atrial fibrillation undergoing hemodialysis, initiating anticoagulation therapy within 90 days of diagnosis was not associated with a reduced risk of ischemic stroke but showed a non-statistically significant trend toward an increased risk of intracerebral hemorrhage. The content presented in this abstract was submitted for the 8th meeting of Society for Clinical Epidemiology in 2026.
